Skip to content

Clinical trials

Phase 2 Arrhythmias, Cardiac trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Arrhythmias, Cardiac Phase: Phase 2 Clear all

31 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20055
20072
20081
20093
20112
20121
20151
20172
20191
20202
20233
20255

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed15
Recruiting6
Terminated5
Unknown status2
Enrolling by invitation1
Active, not recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Heart, Lung, and Blood Institute (NHLBI)3
Wyeth is now a wholly owned subsidiary of Pfizer3
Centro Cardiologico Monzino2
Meshalkin Research Institute of Pathology of Circulation2
Novartis Pharmaceuticals2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1
Anthos Therapeutics, Inc.1
AstraZeneca1
Biosense Webster, Inc.1
Cardurion Pharmaceuticals, Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Arrhythmias, Cardiac31
Atrial Fibrillation7
Tachycardia, Ventricular5
Heart Diseases3
Cardiovascular Diseases2
Ventricular Fibrillation2
Anemia, Sickle Cell1
Arrhythmogenic Right Ventricular Dysplasia1
Atrial Premature Complexes1
Cardiomyopathies1

Trials

Showing 76 to 31 of 31. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.